Objective To measure prescription use intensity and regional variation of psychotropic and 2 important nonpsychotropic drug groups among children with autism spectrum disorders (ASDs) compared with children in the general population.
W
ith increased prevalence of autism spectrum disorder (ASD) diagnoses in children, much attention has focused on their treatment, particularly pharmacotherapy. Recent research reveals high rates of psychotropic use and polypharmacy among children with ASDs. [1] [2] [3] [4] [5] Although risperidone and aripiprazole are the only psychotropics approved by the US Food and Drug Administration for treatment of ASDs (for irritability), many children with ASDs are prescribed other psychotropic regimens. 1, 2, 4 Research on the effectiveness of psychotropics in ASDs is expanding, but the outcomes associated with many drugs remain uncertain. 1, 4 The combination of scant evidence of effectiveness, family desperation, and hope for symptom improvement creates difficult decisions for providers and families caring for these children. Collectively, ASDs represent some of the most complex and challenging pediatric conditions. Study of ASD care patterns provides an opportunity to understand the management of chronic conditions characterized by high degrees of therapeutic uncertainty.
Research on patterns and determinants of prescription use intensity in ASDs has not kept pace with growth in medication use. There is little information about local psychotropic practice patterns in this population; even less is known about the use of nonpsychotropic drugs among children with ASDs. [6] [7] [8] [9] [10] [11] Studies to date have not directly compared the pharmacotherapy experienced by children with ASDs with that of the general pediatric population; this comparison provides context for interpreting treatment patterns observed among children with ASDs. Understanding use and variation will serve as a foundation for future studies of health outcomes associated with diverse treatment patterns; it should also prompt discussion and collective consideration of best practices.
In this study, we measured use of psychotropics and 2 important nonpsychotropic drug groups among children in Northern New England diagnosed with ASDs. We compared their medication use to that of the general pediatric population. Within these 2 patient groups, we analyzed prescription use variation across small geographic hospital service areas (HSAs).
Methods
We used pediatric all-payer administrative data for Northern New England (New Hampshire, Vermont, Maine). The data contain claims for children ages 0-17 years with 1 or more month of enrollment in a commercial or Medicaid insurance plan meeting state reporting requirements, 2007-2010. To achieve statistically stable population necessary for small area variation analyses, we combined the 4 years of data. We identified children with 1 or more inpatient or outpatient diagnosis of ASD (International Classification of Diseases, 9th Revision diagnosis codes 299.0, 299.1 and 299.8, and 299.9) appearing at any time during our observation period, creating a cohort of prevalent (not incident) cases with ASD. The children's insurance enrollment months served as the denominator for prescription drug use measures; all observation months (those preceding and following first observed diagnosis) were included in the ASD cohort denominator. Children without claims evidence of ASD made up the general pediatric population cohort included for comparison.
We used outpatient prescription claims to measure prescription fill events for each person-month of enrollment. We calculated 2 measures of prescription use: (1) prescription fills per person year (PY), the primary measure; and (2) prevalence of use (average annual proportion of the population with any use). Drug measures were calculated overall and for specific drug groups.
Our analysis of psychotropic medications included attention deficit hyperactivity disorder (ADHD) drugs, antidepressants, antipsychotics, benzodiazepines, and centrally acting alpha agonists (analyzed separately from ADHD medications as US Food and Drug Administration approval for ADHD occurred late in our study period). We conservatively did not include antiepileptic drugs in our analysis of pyschotropics because we could not confidently differentiate use for behavioral disturbances from use for seizure management, which introduces substantial risk of measurement error given the high rate of coexisting seizure disorders in children with ASDs. 12 We included benzodiazepines in our analysis of psychotropics because these medications are used both as anxiolytics and for treatment of the behavioral symptoms of catatonia among children with ASDs. 13, 14 Although benzodiazepines also are used for seizure management, their role is most typically abortive (rather than chronic preventive), introducing less risk of measurement error than for other antiepileptics. Our exploration of nonpsychotropics focused on antibiotics and prescription antacids. These medication groups are commonly used in pediatrics, and use is characterized by some degree of therapeutic uncertainty; antacids are being used increasingly in children without clear evidence of effectiveness and antibiotic overuse also remains prevalent. [15] [16] [17] [18] [19] [20] [21] We hypothesized these medications may be used with higher intensity among children with ASDs for a number of reasons, including our practice experience, more frequent contact with clinicians, difficult to interpret symptomatology that may suggest pain, and speculation (albeit controversial) that ASDs may have gastrointestinal or immunologic manifestations.
We measured the prevalence of psychotropic polypharmacy, defined broadly as the observation time-weighted proportion of children using medications from multiple psychotropic drug groups ($1, $2, and $3) in a single calendar year. For overall fill measures, we excluded fluoride claims because use of this product is determined by water fluoridation.
Each patient month was categorized by age, sex, and payer type (Medicaid or commercial). We used residential zip code to assign each person month to one of 69 Dartmouth Atlas of Health Care HSAs. HSAs are relatively self-contained geographic health care markets in which the resident pediatric population receives the majority of medical services from providers within the area. HSAs were derived using Medicare data for adults but were validated with this dataset for pediatric health care using localization indices for both the general pediatric population and the ASD cohort.
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Localization indices are calculated as the percent of health care events for children within an HSA provided by clinicians practicing within that HSA. We included the 19 (of 69) HSAs with 200 or more individuals diagnosed with ASD for small area variation analyses. Within these HSAs, the mean localization for emergency room visits was 73%; the mean for office visits was 70%.
Analyses
For each cohort, we calculated population age-and adjusted prescription use measures overall. Statistical significance of differences between cohorts was calculated using c 2 estimation test. In secondary analyses of prescription use intensity, we calculated sex-adjusted drug use by age group and by payer type. We calculated HSA-level prescription use, adjusted for age, sex, and payer type, for the 19 HSAs with the largest populations with ASD.
Results
Overall, 13 100 children met inclusion criteria for the cohort with ASD (34 584 PYs), and 936 721 children (1.7 million PYs) were included in the general pediatric cohort ( Table I) . Of the ASD cohort PYs, 79.5% were associated with males; 68% were Medicaid insured. In contrast, 46% of the general population PYs were Medicaid insured ( Table I) .
In Northern New England, children diagnosed with ASDs comprised 2.0% of all PYs studied; they received 7.5% of overall prescription fills and 15.6% of the psychotropic fills (Table II ; available at www.jpeds.com, lists medications included in each drug group). Among children with ASDs, the overall prescription fill rate was 16.6 fills per PY; the rate in the general pediatric population was 4.1 per PY (P = .007; Table III) .
Overall psychotropic use among children with ASDs was more than 9-fold that of the general population. Differences in psychotropic use rates between cohorts were greatest for antipsychotics, for which prescription fills among children diagnosed with ASD were more than 22-fold those of the general population; cohort level differences in ADHD medication use compared with the general population were smallest but still nearly 6-fold. Differences were statistically significant for psychotropic use overall and across each category of psychotropic medication (P < .001; Table III) . Prevalence of prescription use paralleled these rates. Among children with ASDs, on average, annually, 46% were prescribed at least 1 psychotropic medication, 23% of the children were prescribed medications from 2 or more distinct psychotropic drug groups, and 8% were prescribed medications from at least 3 distinct psychotropic groups. In contrast, 8% of the general population used 1 or more psychotropic medication in a single year (Table IV; available at www.jpeds.com). Age-stratified psychotropic use patterns revealed an anticipated pattern of increased use with age (data not shown).
Overall, compared with the general population, children with ASD had a 3.5-fold higher rate of prescription antacid use (P < .001); antibiotic use was 20% higher (P < .001; Table III ).
Secondary Analyses of Prescription Use Intensity
Age-stratified analyses revealed notable differences between the youngest members of the cohorts. In children ages 0-2 years, a stage of life that often precedes ASD diagnosis, [22] [23] [24] the rate of antibiotic use among children ultimately diagnosed with ASD was more than 2-fold that of the general population; the rate of antacid use was nearly 5-fold greater. The rate of antacid use was more discrepant All medication measures are based on outpatient fills for oral products. P values calculated using c 2 estimation test. Prescription antacids include proton pump inhibitors and histamine-2 receptor blockers. See Table II for drugs included in each drug group. ADHD treatments do not include alpha agonists (considered separately). Antipsychotics include both first and second generation products. All psychotropics include all psychotropic drug groups listed.
among those aged 3-4 years, where fills in the cohort with ASD were over 8-fold greater than the general population ( Figure) . These age group differences were all statistically significant (P < .001).
In analyses assessing drug use by payer type, we found higher psychotropic drug use among Medicaid-insured children in the general pediatric population. In contrast, within the population with ASD, psychotropic fill rates were similar across payer type. For nonpsychotropics, payer-type differences were similar in the 2 cohorts; antibiotics showed little variation and antacids demonstrated higher Medicaid fill rates in both populations (Table V; available at www.jpeds.com).
Regional Variation
Overall, age-, sex-, and payer-adjusted HSA-level variation was high in the 19 areas studied (HSA characteristics shown in Table VI ; available at www.jpeds.com); all medication use rates except antibiotics and antidepressants varied more than 2-fold across these areas. Of the psychotropics, the greatest Figure. Use of antibiotics and antacids by age, children with ASDs vs general population. Statistical significance was measured by c 2 estimation test for all age groups for both antacids and antibiotics, P < .001.
variation was seen in benzodiazepine use, which varied more than 12-fold across these small areas (5th-95th percentile, nearly 5-fold). Alpha agonist use varied nearly 5-fold (5th-95th percentile, over 3-fold) and ADHD medication use varied nearly 3-fold (5th-95th percentile, nearly 2-fold). Antacid use also showed marked differences across HSAs, varying more than 6-fold (5th-95th percentile, over 3-fold). Antibiotics showed the least variation across HSAs, just 2-fold (5th-95th percentile range, similar) ( Table VII) .
Discussion
In this study, the anticipated high rates of prescription use among children of Northern New England diagnosed with ASDs was dwarfed by marked small area variation. This suggests an important role of physician prescribing patterns as determinants of the overall pharmacotherapy experienced by children with ASDs and reveals divergent care patterns under conditions of high therapeutic uncertainty. The finding that very young children ultimately diagnosed with ASDs receive substantially more antibiotics and antacids than their peers was unexpected and warrants further examination of both causes and consequences. The observed high psychotropic use among children diagnosed with ASD parallels findings of other authors; rates of psychotropic use and polypharmacy fall within the range of those previously published.
1 Some recent studies citing higher rates of use than we observed have included more drug groups; in particular, we did not include anti-epileptics in the psychotropic groups as others have because of the high rates of epilepsy among children with ASDs. 1, 2, 5, 12 Our inclusion of observation months that may precede ASD diagnosis may also reduce estimates of pharmacotherapy intensity. The finding that psychotropic use of this small pediatric subpopulation (2% of children) accounts for 16% of all pediatric psychotropic fills in Northern New England is striking and suggests a need for further study of determinants of prescribing patterns and associated outcomes.
The high rates of antacid and antibiotic use in very young children ultimately diagnosed with ASDs raise new questions. Prior studies suggest the average age of ASD diagnosis ranges from 3-4 years; many children are diagnosed later. [22] [23] [24] Therefore, some children in our cohort experiencing high antacid and antibiotic use may have received these therapies prior to their ASD diagnosis, suggesting symptoms prompting these therapies may precede formal recognition of behavioral manifestations of ASDs. These findings may result from children with ASDs presenting in early years with higher rates of true infections, such as otitis media or pneumonia, or with gastrointestinal complaints. Though some research has suggested children with ASDs have altered immunity and may be prone to gastrointestinal pathology, this remains controversial. [25] [26] [27] [28] [29] Alternatively, these children may demonstrate nonspecific symptoms at this stage of life suggestive of underlying medical problems. The prescribing intensity we observed may simply result from more frequent medical care because of behavioral concerns and, thus, more opportunity to receive prescriptions, or desperation among families and providers to address difficult-to-manage and poorly-understood symptomatology.
High variation in both psychotropic and nonpsychotropic prescription use among children with ASDs across small areas in this relatively homogenous population suggests clinician practice style as an important driver of the pharmacotherapy experience of these children. Of the medications we studied, benzodiazepines showed the greatest HSA-level variation, nearly 5-fold for 5th-95th percentile. Variation in benzodiazepine use may reflect differing comfort with this Drug Enforcement Administration-controlled medication class with substantial potential for side effects. High regional variation was also observed with antacid use, over 3-fold for 5th-95th percentile. This may reflect disagreement over the value of these medications for children. 18, 19, 30, 31 These findings suggest that regions have prescription "fingerprints," or distinct prescribing patterns not entirely driven by the population's illness or caregiver preferences. Understanding this level of variation in health care delivery and the outcomes associated with this variation is crucial to ensuring efficient and effective care across populations. Open dialogue among clinicians on approaches to ASD care and continued focus on practice-based learning should help to identify sources of variation and understand associated outcomes. In addition, given lack of clarity surrounding the best approach to the care of children with ASDs, we must involve families in shared decision making when considering the difficult choices to be made for their children. [32] [33] [34] Our study has limitations. We used a single visit claim associated with ASD International Classification of Diseases, 9th Revision diagnosis code as criteria for inclusion in our cohort with ASD. A recent study demonstrated a high positive predictive value of 2 or more claims to determine a diagnosis of an ASD. 35 Reassuringly, 90% of our cohort with ASD had a second ASD diagnosis in our observation period. The diagnosis of ASD is complex, and as a consequence, region or clinician-specific differences in criteria for diagnoses may vary, resulting in differing levels of identified disease and severity across the regions studied. If such differences exist, they may explain some of the prescription variation we observed. Our study is limited to Northern New England. Our findings may not generalize to populations of children with greater racial and ethnic diversity, although we would not expect to see less variation in more diverse populations. We did not analyze over-the-counter medications not reimbursed by health insurance; this may have resulted in an underestimate of actual drug receipt. In this study describing the range of the pharmacotherapy experience of children diagnosed with ASD, we did not adjust for comorbid conditions and quantify their impact on prescription rates. The presence of comorbid diagnoses has been associated with increased used of psychotropics in the population with ASD, but it is not clear if this reflects differences in health state or differences in tendency to treat. [1] [2] [3] [4] This topic has been researched extensively for adults but not yet for children. [36] [37] [38] Future studies should look explicitly at the complex interaction between visit, treatment, and diagnostic intensity, ideally through data richer than claims so that health state might be ascertained with high validity. Lastly, we included all children not diagnosed with ASD in our general pediatric cohort. The inclusion of a small number of children with serious mental illness in our comparator population will shift our findings of population prescription use differences toward the null and create conservative estimates.
Further research of ASD pharmacotherapy is needed to understand determinants of variation in prescribing, as well as the effectiveness and adverse effects of medications in this population. The higher use of antacids and antibiotics among young children diagnosed with ASDs deserves further exploration and examination of timing relative to diagnosis; this may elucidate presenting symptomatology of these complex disorders. Given the uncertain benefit of most pharmacotherapy in this population, and known adverse effects, shared decision making with children's caregivers should be incorporated into prescribing practices. In addition, the wide variation we have observed across small geographic areas suggests providers should collaborate both regionally and nationally and continue discussions on the best pharmacotherapeutic practices for children with ASDs. n Psychotropics include all of the medication groups above. All medication measures are based on outpatient fills for oral products. Prescription antacids include proton pump inhibitors and histamine-2 receptor blockers. See Table II for drugs included in each drug group. ADHD treatments do not include alpha agonists (considered separately). Antipsychotics include both first and second generation products. All psychotropics includes all psychotropic drug groups listed. 
